ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Genomics

Beam Therapeutics prepares for IPO

by Ryan Cross
October 6, 2019 | APPEARED IN VOLUME 97, ISSUE 39

 

Less than 18 months after Beam Therapeutics launched with its first round of private funding, the gene-editing start-up has filed paperwork for a $100 million initial public offering on Nasdaq. Beam is developing therapies derived from the CRISPR base editors invented in David Liu’s lab at the Broad Institute of MIT & Harvard. Liu’s editors, published in 2016, can change a single nucleotide of DNA into another nucleotide. Beam is working on 12 drug programs, with an initial focus on blood, liver, and eye diseases, as well as CAR T-cell therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment